Heart Health in Blood Cancer Care: What Patients and Families Need to Know image

Heart Health in Blood Cancer Care: What Patients and Families Need to Know

Can't make it to the event?
We send a recording to all registered participants of the event!
Jul 29, 2026
01:00PM - 02:00PM EDT
Online Event
Overview

Join the HealthTree Foundation for an essential webinar, "Heart Health in Blood Cancer Care: What Patients and Families Need to Know," featuring expert cardiologist Dr. Orly Leiva. Discover what blood cancer patients need to know about the cardiovascular system and learn practical strategies to safeguard your heart health during and after treatment. Register today to gain the vital knowledge and tools needed to navigate your care journey with confidence.

Agenda
1:00 PM
Introduction
Dalton Bean

Dalton introduces the agenda and our featured speaker Dr. Orly Leiva

1:05 PM
Presentation
Orly Leiva, MD

Dr. Leiva talks about heart health for blood cancer patients

1:35 PM
Questions and Answers
Audience

Come with your questions and we will answer them! 

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Healthtree contact Orly Leiva, MD

Orly Leiva, MD

Dr. Leiva is an Advanced Heart Failure and Transplant Fellow at the University of Chicago. Their clinical research interests include cardio-oncology, cardiac critical care, interventional cardiology, thrombosis, and bridging the gap between hematology and cardiology. They are particularly interested in cardiovascular and thrombotic outcomes and risk factors in patients with hematologic malignancies, particularly myeloproliferative neoplasms.